News
GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...
GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.
The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...
The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.
The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination ...
StockStory.org on MSN21h
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To KnowA number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.
Health-care companies fell as traders hedged their bets on the outlook for growth in the sector. Insurers, including Elevance, which recently warned of cost pressures from its Affordable Care Act ...
StockStory.org on MSN21h
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling TodayShares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after ...
Arbitrators cleared the way for the long-delayed $53 billion acquisition after Exxon tried to pre-empt the deal. 3M raised its full-year earnings outlook after beating expectations in the second ...
FRANKFURT: European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by ...
19h
MedPage Today on MSNResearchers Detail Alarming Rise in GI Cancers Among Young PeopleIn addition to obesity, modifiable risk factors include a low-quality diet (such as high consumption of processed meats, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results